专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20110207788A1 5-Ring Heteroaromatic compounds and their use as binding partners for 5-ht5 receptors 有权
标题翻译： 5环杂芳族化合物及其作为5-ht5受体的结合伴侣的用途
公开(公告)号：US20110207788A1
公开(公告)日：2011-08-25
申请号：US11990731
申请日：2006-08-21
申请人： Wilhelm Amberg , Astrid Netz , Andreas Kling , Michael Ochse , Udo Lange , Andreas Haupt , Francisco Javier Garcia-Ladona , Wolfgang Wernet , Alfred Hahn
发明人： Wilhelm Amberg , Astrid Netz , Andreas Kling , Michael Ochse , Udo Lange , Andreas Haupt , Francisco Javier Garcia-Ladona , Wolfgang Wernet , Alfred Hahn
IPC分类号： A61K31/42 , C07D233/00 , C07D249/14 , C07D261/06 , A61K31/415 , A61K31/4196 , A61P25/28
CPC分类号： C07D417/04 , C07D231/38 , C07D233/70 , C07D233/88 , C07D249/14 , C07D405/04 , C07D409/04 , C07D413/04
摘要： The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.
摘要翻译：本发明涉及通式（I）的5-环杂芳族化合物，其用于治疗和/或预防疾病的用途，以及含有它们的药物。

32. 发明授权

US4754807A Sand screen for production oil wells 失效
标题翻译：砂筛生产油井
公开(公告)号：US4754807A
公开(公告)日：1988-07-05
申请号：US023219
申请日：1987-03-09
申请人： Udo Lange
发明人： Udo Lange
IPC分类号： B01D29/15 , E21B43/08
CPC分类号： E21B43/088 , B01D29/15
摘要： In oil and gas production installations, formation sand may pass through sand screens and enter the tubing, causing damage and increasing abrasive wear. Gravel used to prevent this often leaves gaps and lets formation sand pass through. The invention eliminates such gaps by incorporating an ordinary polished bore (11) in the sand screen (4, 7) to land and seal off the wash pipe (9). Two concentric tubes (4a, 4b) are connected to each other by a collar (17) whose inside surface is a polished bore (11) and whose outer side has supports (17a, 17b) for the tubes (4a, 4b) and the upset screens.
摘要翻译：在石油和天然气生产设备中，地层砂可能通过砂筛并进入管道，造成损坏并增加磨损。用于防止这种砂石经常留下间隙并使地层砂通过。本发明通过将普通的抛光孔（11）结合在筛网（4,7）中来抵消和密封洗涤管（9）而消除了这种间隙。两个同心管（4a，4b）通过其内表面是抛光孔（11）并且其外侧具有用于管（4a，4b）的支撑件（17a，17b）的套环（17）彼此连接，并且沮丧的屏幕。

33. 发明授权

US08563617B2 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
公开(公告)号：US08563617B2
公开(公告)日：2013-10-22
申请号：US12706326
申请日：2010-02-16
申请人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Homberger , Mario Mezler , Charles W. Hutchins
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Homberger , Mario Mezler , Charles W. Hutchins
IPC分类号： A61K31/16 , C07C215/70
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.

34. 发明申请

US20120295881A1 TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权
标题翻译：四环素和吲哚衍生物，含有它们的药物组合物及其在治疗中的使用
公开(公告)号：US20120295881A1
公开(公告)日：2012-11-22
申请号：US13546434
申请日：2012-07-11
申请人： Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Frauke Pohlki , Charles W. Hutchins
发明人： Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Frauke Pohlki , Charles W. Hutchins
IPC分类号： A61K31/18 , C07D233/84 , A61K31/4164 , A61P25/18 , A61K31/397 , C07D403/12 , A61K31/4178 , A61P25/00 , C07C311/14 , C07D205/04
CPC分类号： C07D233/84 , C07C311/05 , C07C311/10 , C07C311/14 , C07C2601/02 , C07C2601/04 , C07C2602/08 , C07C2602/10 , C07D205/04 , C07D403/12
摘要： The present invention relates to tetraline and indane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such tetraline and indane derivatives, and the use of such tetraline and indane derivatives for therapeutic purposes. The tetraline and indane derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及式（I）的四氢化萘和二氢化茚衍生物或其生理上耐受的盐。本发明涉及包含这种四氢化萘和二氢化茚衍生物的药物组合物，以及这些四氢化萘和二氢化茚衍生物用于治疗目的的用途。四氢化萘和茚满衍生物是GlyT1抑制剂。

35. 发明授权

US08242102B2 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor 有权
标题翻译：喹啉化合物适用于治疗对血清素5-HT6受体调节作用的疾病
公开(公告)号：US08242102B2
公开(公告)日：2012-08-14
申请号：US12532407
申请日：2008-03-23
申请人： Sean Colm Turner , Andreas Haupt , Wilfried Braje , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Alfred Hahn, legal representative , Matthias Mayrer
发明人： Sean Colm Turner , Andreas Haupt , Wilfried Braje , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer
IPC分类号： A61K31/397 , C07D215/00
CPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R is a moiety of the formula wherein A, R1 to R4 are as defined in the claims and the specification, n is 0, 1 or 2; m is 0, 1, 2 or 3; Ra, Rb are independently selected from the group consisting of halogen, CN, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C(O)Raa, C(O)NRccRbb and NRccRbb; X is CH2, C(O), S, S(O) or S(O)2; which is located in the 3- or 4-position of the quinoline ring; Ar is a radical Ar1, Ar2—Ar3 or Ar2—O—Ar3, wherein Ar1, Ar2 and Ar3 are each independently selected from the group consisting of aryl or hetaryl wherein aryl or hetaryl moieties may be unsubstituted or may carry 1, 2, 3 substituents Rx, wherein and physiologically tolerated acid addition salts and the N-oxides thereof.
摘要翻译：本发明涉及新颖的喹啉化合物。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。其中R是下式的部分，其中A，R 1至R 4如权利要求和说明书中所定义，n为0,1或2; m为0,1,2或3; R a，R b独立地选自卤素，CN，C 1 -C 4 - 烷基，C 1 -C 4卤代烷基，C 1 -C 4 - 烷氧基，C 1 -C 4卤代烷氧基，C（O）R aa，C（O）NR c R b b 和NRccRbb; X是CH 2，C（O），S，S（O）或S（O）2; 其位于喹啉环的3-或4-位; Ar是Ar1，Ar2-Ar3或Ar2-O-Ar3基团，其中Ar1，Ar2和Ar3各自独立地选自芳基或杂芳基，其中芳基或杂芳基部分可以是未取代的或可以携带1,2,3 取代基Rx，其中和生理上耐受的酸加成盐及其N-氧化物。

36. 发明申请

US20100311755A1 1,2,4,-TRIAZIN-3,5-DIONE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 有权
标题翻译： 1,2,4，-TRIAZIN-3,5-DIONE适用于治疗多巴胺D3受体调节障碍的化合物
公开(公告)号：US20100311755A1
公开(公告)日：2010-12-09
申请号：US12740714
申请日：2008-10-31
申请人： Wilfried Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Herve' Geneste , Karla Drescher , Liliane Unger , Ana Lucia Jongen-Relo , Anton Bespalov
发明人： Wilfried Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Herve' Geneste , Karla Drescher , Liliane Unger , Ana Lucia Jongen-Relo , Anton Bespalov
IPC分类号： A61K31/53 , C07D253/07 , A61P25/00 , A61P25/18 , A61P25/30 , A61P13/12
CPC分类号： C07D403/12
摘要： The invention relates to compounds of the formula I: wherein A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups; R1 is selected from the group consisting of hydrogen, C1-C3 alkyl and fluorinated C1-C3 alkyl; R2 is hydrogen, halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R3 is selected from the group consisting of branched C4-C6 alkyl and C3-C6 cycloalkyl, and R4 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C3-alkyl and fluorinated C3-C6 cycloalkyl. and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
摘要翻译：本发明涉及式I化合物：其中A是链长为4-6个碳原子的饱和或不饱和烃链，烃链未被取代或被1,2或3个甲基取代; R1选自氢，C1-C3烷基和氟化C1-C3烷基; R2是氢，卤素，氰基，C1-C3烷基，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R3选自支链C4-C6烷基和C3-C6环烷基，R4为C1-C6烷基，C3-C6环烷基，氟化C1-C3-烷基和氟化C3-C6环烷基。以及这些化合物的生理上耐受的盐及其N-氧化物。本发明还涉及包含至少一种式I化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂或多巴胺D3的病症的方法所述方法包括向有需要的受试者施用有效量的至少一种式I化合物或生理学上耐受的酸加成盐。

37. 发明申请

US20100292271A1 Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor 有权
标题翻译：适用于治疗对血清素-5-HT6受体调节作用的疾病的喹啉化合物
公开(公告)号：US20100292271A1
公开(公告)日：2010-11-18
申请号：US12664394
申请日：2008-08-06
申请人： Sean Colm Turner , Wilfried Braje , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer
发明人： Sean Colm Turner , Wilfried Braje , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer
IPC分类号： A61K31/47 , C07D215/36 , A61P25/28 , A61P25/18 , A61P25/30 , A61P3/04 , A61P25/00
CPC分类号： C07D487/04 , C07D471/04 , C07D519/00
摘要： The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, R1, Rb, X and Ar are as defined in claim 1.
摘要翻译：本发明涉及式（I）的新颖喹啉化合物及其盐。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。在式（I）中，R是式（R）的部分，其中*表示与喹啉基的结合位点，其中A，B，X'，Y，Q，R 1，R 2，R 3，R 4，R 5， n，p，q，R 1，R b，X和Ar如权利要求1中所定义。

38. 发明申请

US20100137280A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 有权
标题翻译：适用于治疗响应调节SEROTONIN 5-HT6受体的疾病的AZETIDIN化合物
公开(公告)号：US20100137280A1
公开(公告)日：2010-06-03
申请号：US12532406
申请日：2008-03-20
申请人： Thomas Schultz, SR. , Wilfried Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Matthias Mayrer
发明人： Thomas Schultz, SR. , Wilfried Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Matthias Mayrer
IPC分类号： A61K31/404 , A61K31/437 , A61K31/4184 , A61K31/416 , C07D403/10 , C07D413/02 , C07D401/14 , C07D471/04 , C07D487/04 , A61K31/506 , A61P25/00 , A61P3/04 , A61P25/30 , A61P25/18
CPC分类号： C07D471/04 , C07D403/04
摘要： The present invention relates to compounds of formula (I) wherein A is C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-hydroxyalkyl, C2-C6-alkenyl, C2-C6-halo-alkenyl, C3-C6-cycloalkyl, aryl-C1-C4-alkyl, aryl-C2-C4-alkenyl, aryl or hetaryl, is a single or double bond; X1 and X2 are N, CRx1, NRx2, or CRx3Rx4; Rx1, Rx3 and Rx4 are H, halogen, CN, NO2, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, etc. or two geminal radicals Rx3 and Rx4 together with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro-annulated ring; Rx2 is hydrogen, C1-C6-alkyl, C1-C6-alkylcarbonyl, C1-C6-haloalkyl, etc.; or two vicinal radicals Rx1, Rx2, Rx3 or Rx4 together with X1 and X2 form a five- or six-membered carbocyclic or heterocyclic fused ring; Y1, Y2 and Y3 are N or CRy; Ry is H, halogen, CN, NO2, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, C1-C6-haloalkyl, etc.; wherein a maximum of 3 of the radicals X1, X2, Y1, Y2 and Y3 are selected from NRx1 and N; R1 is hydrogen, C1-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, etc.; R2 is C1-C4-alkyl or C1-C4-haloalkyl; n is 0, 1 or 2; physiologically tolerated acid addition salts and the N-oxides thereof, pharmaceutical composition comprising them, a method for treating medical disorders selected from diseases of the central nervous system, addiction diseases or obesity, said method comprising administering an effective amount of such compounds to a subject in need and the use of such a compound for preparing a pharmaceutical compositions.
摘要翻译：本发明涉及式（I）化合物，其中A为C 1 -C 6 - 烷基，C 1 -C 6 - 卤代烷基，C 1 -C 6羟基烷基，C 2 -C 6 - 烯基，C 2 -C 6 - 卤代烯基，C 3 -C 6 - 环烷基，芳基-C 1 -C 4烷基，芳基-C 2 -C 4 - 烯基，芳基或杂芳基，是单键或双键; X1和X2是N，CRx1，NRx2或CRx3Rx4; Rx1，Rx3和Rx4是H，卤素，CN，NO2，C1-C6-烷基，C1-C6-烷氧基，C1-C6-烷基羰基等，或两个偕根基Rx3和Rx4与它们所在的碳原子一起结合可形成羰基或3-至6-元碳环或杂环螺环状环; Rx2是氢，C1-C6-烷基，C1-C6-烷基羰基，C1-C6-卤代烷基等; 或两个连位基Rx1，Rx2，Rx3或Rx4与X1和X2一起形成五元或六元碳环或杂环稠环; Y1，Y2和Y3为N或CRy; Ry是H，卤素，CN，NO 2，C 1 -C 6 - 烷基，C 1 -C 6 - 烷氧基，C 1 -C 6 - 烷基羰基，C 1 -C 6 - 卤代烷基等; 其中基团X1，X2，Y1，Y2和Y3中的最多3个选自NRx1和N; R1是氢，C1-C6-烷基，C1-C6-羟基烷基，C1-C6-卤代烷基等; R2是C1-C4-烷基或C1-C4卤代烷基; n为0,1或2; 生理耐受的酸加成盐及其N-氧化物，包含它们的药物组合物，治疗选自中枢神经系统疾病，成瘾疾病或肥胖症的医学病症的方法，所述方法包括向受试者施用有效量的这些化合物并且使用这种化合物来制备药物组合物。

39. 发明申请

US20090143383A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 有权
标题翻译：适用于治疗多巴胺D3受体调节症状的ARYLOXYYHYLAMINE化合物
公开(公告)号：US20090143383A1
公开(公告)日：2009-06-04
申请号：US12296739
申请日：2007-04-13
申请人： Roland Grandel , Wilfried Martin Braje , Andreas Haupt , Sean Colm Turner , Udo Lange , Karla Drescher , Liliane Unger
发明人： Roland Grandel , Wilfried Martin Braje , Andreas Haupt , Sean Colm Turner , Udo Lange , Karla Drescher , Liliane Unger
IPC分类号： A61K31/5377 , C07D413/02 , C07D403/02 , A61K31/44 , A61K31/506 , C07D401/02
CPC分类号： C07D213/76 , C07D239/69
摘要： The present invention relates to aryloxyethylamine compounds of the formula I and the physiologically tolerated acid addition salts thereof. The variables have the meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式I的芳氧基乙胺化合物及其生理上耐受的酸加成盐。变量具有权利要求书和说明书中给出的含义。本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。

40. 发明申请

US20090131452A1 BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 有权
标题翻译：适用于治疗依托莫司汀5-HT6受体调节的病症的苯并呋喃半导体化合物
公开(公告)号：US20090131452A1
公开(公告)日：2009-05-21
申请号：US12262455
申请日：2008-10-31
申请人： Wilfried Martin Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer , Ana Jongen-Relo , Anton Bespalov , Min Zhang
发明人： Wilfried Martin Braje , Sean Colm Turner , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer , Ana Jongen-Relo , Anton Bespalov , Min Zhang
IPC分类号： A61K31/496 , C07D295/182 , C07D405/12 , A61P25/00 , A61K31/495
CPC分类号： C07D295/12 , C07D405/12
摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 hydrogen, fluorine C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, C1-C2 alkyl fluorinated C1-C2 alkyl C1-C2 alkoxy or fluorinated C1-C2 alkoxy; and R6 is hydrogen, fluorine or chlorine.
摘要翻译：本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。其中R1是氢或甲基R2是氢或甲基R3氢，氟C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基或氟化C1-C4烷基; R5是氢，氟，C1-C2烷基氟化C1-C2烷基C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟或氯。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式